Publications
View and download slide summaries of the latest original articles focusing on cytokine signalling therapies within rheumatoid arthritis. All materials produced by the CSF team are subsequently reviewed and approved by individual Steering Committee members.
January 2022
関節リウマチにおけるウパダシチニブによる関節破壊進行抑制: SELECT フェーズ3プログラムからの1年目結果
Rheumatology (Oxford). 2021. Epub ahead of print. doi: 10.1093/rheumatology/keab861
.Keywords:
March 2021
関節リウマチにおけるウパダシチニブ: 第三相試験横 断的ベネフィットリスクバランス評価
Drug Saf. 2021 Feb 2. DOI: 10.1007/s40264-020-01036-w
Upadacitinib 15 mg has a favourable benefit–risk profile according to an assessment of data from the phase III SELECT clinical trial programme.In this review of data for the once-daily, oral JAK inhibitor, Conaghan PG, et al. provided insights into the benefit–risk profile of upadacitinib in approximately 4400 patients with RA. Based on pooled data from five pivotal studies, benefits and risks were assessed up to the time of regulatory submission, and additional long-term integrated safety revie...Keywords:
November 2020
関節リウマチにおけるUpadacitinibの安全性プロファイル:SELECT フェーズIII 臨床試験からの統合解析
Ann Rheum Dis 2020 DOI:10.1136/annrheumdis-2020-218510
This integrated Phase III safety analysis of UPA showed that UPA had a similar profile to ADA and MTX for serious infections, malignancies, and thromboembolic events. Patients receiving UPA had increased risk of HZ and creatine phosphokinase elevation versus ADA.This integrated Phase III safety analysis of UPA examined >3500 RA patients and 4000 patient-years of exposure. Data were pooled from 3834 patients in SELECT-NEXT, SELECT-BEYOND, SELECT-MONOTHERAPY, SELECT-COMPARE and SELECT-EARLY studie...
December 2019
Highlights of 2019
Please click the links below to go to the CSF review of each paper
2019 was another remarkable year in cytokine signalling. We can be optimistic that clinical practice for inflammatory arthritis will continue to improve, with promising long-term safety data supporting the use of established JAK inhibitors; tofacitinib and baricitinib, in addition to exciting phase III clinical data for filgotinib and newly approved upadacitinib. You can find the most notable papers, as selected by CSF Steering Committee Chair Professor Iain McInnes, with links to their respecti...
August 2019
関節リウマチ患者におけるメトトレキサート併用下かつ効果 不十分例でスイッチした際のUpadacitinib または Adalimumab の48週安全性と有効性
Ann Rheum Dis 2019 DOI: 10.1136/annrheumdis-2019-215764
Consistent with Wk26 data, significantly more UPA patients achieved LDA and remission versus ADA and PBO over 48 weeks. RA patients often change therapy due to inadequate response and intolerance. The SELECT COMPARE study was designed to explore switching to JAK inhibitors from TNF inhibitors without a wash-out period (and vice versa). The long-term safety and efficacy of UPA was compared to ADA and PBO in MTX-IR.1629 patients were blindly assigned 2:2:1 to; UPA 15mg QD, ADA 40mg Q2W and PBO, wi...